{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bacterial-vaginosis/prescribing-information/oral-metronidazole/","result":{"pageContext":{"chapter":{"id":"39735e82-4c9f-5aa2-97c7-1496f80b7c1f","slug":"oral-metronidazole","fullItemName":"Oral metronidazole","depth":2,"htmlHeader":"<!-- begin field bd4ec8ea-04b9-4b02-b08a-040886f80303 --><h2>Oral metronidazole</h2><!-- end field bd4ec8ea-04b9-4b02-b08a-040886f80303 -->","summary":"","htmlStringContent":"<!-- begin item 71991233-62b0-474e-bfc0-2674117e389d --><!-- end item 71991233-62b0-474e-bfc0-2674117e389d -->","topic":{"id":"865cdea2-9043-57ef-8b25-031205cdd37d","topicId":"afc41d7e-87dd-41b7-bbc7-b86b9168703c","topicName":"Bacterial vaginosis","slug":"bacterial-vaginosis","lastRevised":"Last revised in October 2018","chapters":[{"id":"f7fe1c4f-d424-53b7-9e1d-2e724534b550","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ff6b3e14-7f5b-50db-8eee-ad227bf399c7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9d2f35ec-215f-5ee1-b407-2c5b68e931b0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"06809c66-f539-5454-a18a-ff951a80494b","slug":"changes","fullItemName":"Changes"},{"id":"0872ed37-dd2a-58ae-ba58-ecd7dd9c964e","slug":"update","fullItemName":"Update"}]},{"id":"b96f10d4-f421-527a-bcaf-8e5e46afb0b5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7b27492c-f7b2-5bdf-8be5-596f1ad99050","slug":"goals","fullItemName":"Goals"},{"id":"8b94b860-815d-522b-b4fe-461ef978443a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b1dc3d72-ac27-5757-be13-e2015daa0798","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8cef0513-bbd8-5919-961e-a28c7cfdd421","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7bc7f747-27e8-5daa-9d10-380bdcd0f2e2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e58af854-9d1b-51ce-a49a-83df8540a21a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d6cf6c66-7d92-5d41-933f-a9a879fa36d4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ebdd3d77-69b1-523d-a4ac-4de1bd53fcfe","slug":"definition","fullItemName":"Definition"},{"id":"7f17b28f-8990-5777-98b2-0b0a488d883f","slug":"contributing-factors","fullItemName":"Contributing factors"},{"id":"276cab7f-4264-59d9-8986-e8de8d64e45e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9a592036-9b11-587b-8576-77aac8d2b2ef","slug":"complications","fullItemName":"Complications"}]},{"id":"a011fb71-c488-53bd-b5ca-10e92c77583a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b250f8fd-847f-5844-a2d6-32014c81a438","slug":"assessment","fullItemName":"Assessment"},{"id":"e655909b-34b2-55ce-8897-68a2131e1a0c","slug":"examination-investigations","fullItemName":"Examination and investigations"},{"id":"5cc72fff-2222-558d-815e-907a5a25c2ef","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0ae8498b-179a-5f9f-8ece-c5004a1ed196","fullItemName":"Management","slug":"management","subChapters":[{"id":"c43aecb1-cb55-5433-a0ce-81481bc43060","slug":"women-who-are-not-pregnant","fullItemName":"Scenario: Women who are not pregnant"},{"id":"e17bea46-46ca-5a5a-8f23-6d2541ef18b2","slug":"women-who-are-pregnant","fullItemName":"Scenario: Women who are pregnant"}]},{"id":"ff8ddbda-8b29-5d43-ad60-5aeb14b120d3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"39735e82-4c9f-5aa2-97c7-1496f80b7c1f","slug":"oral-metronidazole","fullItemName":"Oral metronidazole"},{"id":"5eef68f3-35a3-5708-a789-014713e8af64","slug":"intravaginal-metronidazole","fullItemName":"Intravaginal metronidazole"},{"id":"ecf84ab7-5f32-5135-a8c2-b302e217480a","slug":"intravaginal-clindamycin","fullItemName":"Intravaginal clindamycin"}]},{"id":"dbca4e81-4cb5-5161-95af-5aed06ab1909","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bab503ee-9268-578a-957b-b6f29998ba50","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a1542e98-52d3-5650-8f50-017cdafb6bb1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dddaaa3b-0dea-5b97-a24a-18f6f861a9b4","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"305419c2-e2ba-51d7-b38f-9d98fdb980ed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b64a9957-d6e0-5d40-9465-e092bfde8548","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"748d8b76-5aee-5fe6-898a-43bbffd5751b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efc1492f-d327-53ae-b257-f0f17e740c27","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ff8ddbda-8b29-5d43-ad60-5aeb14b120d3","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"db320f0a-caff-51d6-b984-f40ff890c3e8","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7ca77cb8-4612-4129-9083-a77700be9ebc --><h3>What are the contraindications and cautions?</h3><!-- end field 7ca77cb8-4612-4129-9083-a77700be9ebc -->","summary":"","htmlStringContent":"<!-- begin item 3d823baa-56ec-4934-8d31-a77700be9c66 --><!-- begin field 3e0dad0b-cfc7-40c5-8cb1-a77700be9ebc --><ul><li><strong>Do not prescribe oral metronidazole to women with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li></ul></li><li><strong>Prescribe oral metronidazole with caution to women with:</strong><ul><li>Severe liver disease or hepatic encephalopathy — prescribe a third of the daily dose once daily.</li><li>Active or chronic severe peripheral and central nervous system disease — there is a risk of neurological aggravation.</li><li>Cockayne syndrome — cases of severe hepatotoxicity/acute hepatic failure (including cases with a fatal outcome with very rapid onset after treatment initiation in people with Cockayne syndrome) have been reported with products containing metronidazole for systemic use (oral and suppositories).<ul><li>Only prescribe metronidazole after careful benefit-risk assessment and only if no alternative treatment is available.</li><li>Perform liver function tests just prior to the start of treatment, during treatment, and at the end of treatment until liver function is within normal ranges, or until the baseline values are reached.</li><li>Advise the person to immediately report any symptoms of potential liver injury to their doctor and stop taking metronidazole.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">ABPI, 2017</a>]</p><!-- end field 3e0dad0b-cfc7-40c5-8cb1-a77700be9ebc --><!-- end item 3d823baa-56ec-4934-8d31-a77700be9c66 -->","subChapters":[]},{"id":"8a94a990-e089-5e55-a2ea-f25b8d679c6c","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d4c63b11-87f4-4166-9d22-a77700bebbc1 --><h3>What are the adverse effects?</h3><!-- end field d4c63b11-87f4-4166-9d22-a77700bebbc1 -->","summary":"","htmlStringContent":"<!-- begin item af722bf1-7dfb-4c19-b097-a77700beb9d9 --><!-- begin field aabf76f7-5272-451a-84f9-a77700bebbc1 --><ul><li><strong>Adverse effects of oral metronidazole include: </strong><ul><li><strong>Very rare </strong>— arthralgia, myalgia, ataxia, darkening of urine, dizziness, drowsiness, headache, pruritus, rash, erythema multiforme, hepatitis, jaundice, leucopenia (on prolonged or intensive therapy), pancytopenia, thrombocytopenia, pancreatitis, peripheral neuropathy (on prolonged or intensive treatment), psychotic disorders, transient epileptiform seizures (on prolonged or intensive treatment), and visual disturbances.</li><li><strong>Frequency not known </strong>— anorexia, aseptic meningitis, furred tongue, gastro-intestinal disturbances, nausea, vomiting, oral mucositis, taste disturbances, and optic neuropathy.</li><li>Severe bullous skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or acute generalised exanthematous pustulosis (AGEP) have been reported. If symptoms/signs are present, treatment must be immediately discontinued.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BNF 75, 2018</a>]</p><!-- end field aabf76f7-5272-451a-84f9-a77700bebbc1 --><!-- end item af722bf1-7dfb-4c19-b097-a77700beb9d9 -->","subChapters":[]},{"id":"7db62b4a-296b-56e6-b11e-f369261bf431","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 800f2153-f3b9-4b71-aaef-a91100cd5c3e --><h3>What are the possible drug interactions?</h3><!-- end field 800f2153-f3b9-4b71-aaef-a91100cd5c3e -->","summary":"","htmlStringContent":"<!-- begin item 25b39794-2dcd-445a-bd5d-a91100cd5905 --><!-- begin field 198c0452-d335-43c0-8ca3-a91100cd5c3e --><ul><li><strong>Drug interactions associated with oral metronidazole include:</strong><ul><li><strong>Alcohol</strong> — some people taking oral metronidazole experience a disulfiram-like reaction (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness) with alcohol.<ul><li>Although there is no conclusive evidence to support this interaction, warn the person that they <em>might</em> experience this reaction if they drink alcohol whilst taking metronidazole. Alcohol should be avoided during treatment with metronidazole and for at least 48 hours afterwards.</li></ul></li><li><strong>Anticoagulants</strong> — the anticoagulant effects of warfarin and acenocoumarol can be markedly increased by metronidazole. There is no interaction with heparin. <ul><li>Monitor the international normalized ratio (INR) if concurrent treatment is indicated, and adjust the anticoagulant dose accordingly.</li><li>Warn the person of the possible risk of increased bruising and bleeding, and advise them on when to seek medical help.</li></ul></li><li><strong>Ciclosporin</strong> — people receiving concurrent metronidazole and ciclosporin are at risk of elevated serum ciclosporin levels.<ul><li>When co-administration of metronidazole and ciclosporin is necessary, monitor serum ciclosporin and creatinine levels closely.</li></ul></li><li><strong>Lithium</strong> — raised lithium levels accompanied by evidence of possible renal damage has been reported in people treated simultaneously with lithium and metronidazole.<ul><li>Before starting metronidazole in a person taking lithium, seek specialist advice about tapering or stopping lithium treatment.</li><li>If concurrent treatment is unavoidable, closely monitor plasma concentrations of lithium, creatinine, and electrolytes.</li></ul></li><li><strong>Phenobarbital or phenytoin</strong> — people receiving phenobarbital or phenytoin metabolize metronidazole at a much greater rate than normal, thereby reducing the half-life to approximately 3 hours. In addition, both metronidazole and phenytoin can increase the risk of peripheral neuropathy.</li></ul></li><li><strong>Oral hormonal contraceptives </strong>— additional contraceptive precautions are <em>not</em> required during or after courses of metronizadole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods </a>  and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete list of possible drug interactions of </strong><strong>metronizadole</strong><strong><strong>,</strong> </strong>see the <a data-hyperlink-id=\"5203f819-92f2-4ec0-b745-a94a00ee63e5\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) and the <a data-hyperlink-id=\"3eb72c95-6193-4a8b-81f0-a94a00ee64a5\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BNF 75, 2018</a>]</p><!-- end field 198c0452-d335-43c0-8ca3-a91100cd5c3e --><!-- end item 25b39794-2dcd-445a-bd5d-a91100cd5905 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}